Antidiabetic Dapagliflozin

Pin
Send
Share
Send

He mea hoʻonaninani ka papa inoa o nā lāʻau antidiabetic i loko o nā lāʻau lapaʻau (me ke ʻano o ka mea ʻai meaʻai, ka lāʻau lapaʻau, nā huaora), ʻelua a me ke ʻano lāʻau lapaʻau, ʻano mahalo. A eia hou, nā lāʻau lapaʻau hou, e like me nā hoʻokolohua, hōʻike i nā hopena hōʻoiaʻiʻo hou aku. ʻO kekahi o kēia mau lāʻau lapaʻau, kahi paʻa i ka maʻi maʻi maʻi, ʻo Forsiga e pili ana i ka dapagliflozin.

ʻO Dapagliflozin kahi lāʻau lapaʻau hypoglycemic no ka hoʻohana waha ma ka maʻi diabetes 2 ʻano. No dapagliflozin, ʻo ka inoa inoa inoa o ka honua no ka maʻi ʻo Forxiga.

ʻO ka hoʻonohonohoʻana o ka lāʻau lapaʻau a me ke ʻano o ka hoʻokuʻu

I loko o ke keʻena lāʻau lapaʻau, kūʻai aku ʻo Dapagliflozin e like me nā papa melemele. Ma muli o ka nui, ua hūʻā ʻia lākou me ka hōʻailona ʻana i ka "5" ma ka mua a me "1427" ma ka ʻaoʻao, a me ke daimana paha me ka hōʻailona me "10" a me "1428".

Ma kekahi pā i loko o nā mea i hoʻonoho ʻia me 10 pcs. ʻO nā pōpō. I kēlā me kēia pahu kīpē he 3 a 9 paha o ia mau papa .. ʻAi nā bli a he 14 mau ʻāpana pākahi. I loko o kahi pahu o nā papa like i hiki ke loaʻa i ʻelua a ʻehā paha.

ʻO 3 mau makahiki kahi e noho ai ke ola o ka lāʻau. No dapagliflozin, ʻo ke kumukūʻai ma ke kaulahao kūʻai aku mai 2497 mau rubles.

ʻO ka mea hana nui o ka lāʻau dapagliflozin. Ma kahi o ia mea, ua hoʻohana ʻia nā hoʻopihapiha: cellulose, lactose maloʻo, silicon dioxide, crospovidone, magnesium stearate.

Lapaʻau

ʻO ka papa hana, dapagliflozin, he potent inhibitor (SGLT2) o ka sodium-depend type type 2 glucose transporter. Hōʻike ʻia i loko o nā aʻalolo, ʻaʻole ia i ʻike ʻia i kekahi mau mea kino a me nā ʻāpana (70 mau ʻano like me ka hoʻāʻo). ʻO SGLT2 ka mea nui e lawe ai i ka glucose reabsorption.

ʻAʻole kū kēia kaʻina me ka maʻi type 2, ke ʻano o ka hyperglycemia. Ma ka hoʻokaʻawale ʻana i ka hoʻoneʻe glucose, hoʻemi ʻia ka mea pale i kona reabsorption i loko o nā pūlū a ua hoʻokuʻu ʻia. Ma muli o kēia hopena, hōʻemi ka meli - ma ka ʻōpū ʻole a ma hope o ka hoʻomaʻamaʻa ʻana, hoʻomaikaʻi hou nā waiwai o ka hemoglobin glycosylated.

Hiki ke ʻike ʻia ka hopena glucosuric ma hope o ke ʻano o hoʻokahi mau lāʻau lapaʻau a hiki i ka hopena o ka papa o ka mālama ʻana.

ʻO ka nui o nā glucose i lawe ʻia e pili ana i ka nui o ke kōpaʻa a me ka helu filtration glomerular rate. ʻAʻole pili ka mea pale kino i ka hana kūlohelohe o kona ake ponoʻī. Kūʻokoʻa kona mau hana i ka hana o ka insulin a me ka pae o ka ʻike ʻana iā ia.

ʻO nā hoʻokolohua me ka lāʻau lapaʻau ua hōʻoia i ka holomua o ka moku'āina o nā b-cell i kuleana no ka synthesis o ka hoʻomau i ka insulin.

Hoʻopau ke kulu ma kēia ala hoʻonāukiuki i ka hoʻohana ʻana i kaloli a me ka nalowale o ka momona nui, he liʻiliʻi diuretic ka hopena.

ʻAʻole hopena ka lāʻau lapaʻau i nā mea hoʻohele glucose hou e hoʻohele ʻia ma ke kino. Ke SGLT2, hōʻike ʻo dapagliflozin i kahi koho o 1,400 mau manawa i ʻoi aku i kona SGLT1, nona ke kuleana o ka hoʻopio o ka glucose i loko o ka ʻōpū.

Lapaʻau lāʻau

Me ka hoʻohana ʻana o Forsigi e ka maʻi maʻi maʻi a me nā poʻe ola olakino ma ka hoʻokolohua, ua ʻike ʻia kahi hoʻonui o ka hopena glucosuric. Ma nā helu kikoʻī, e like me kēia: no 12 mau hebedoma, lawe aku ka maʻi maʻi i ka lāʻau ma ka 10 gm / lā.

I ka maʻi me ka lua o ke ʻano maʻi maʻi i hoʻohana i kēia algorithm no nā makahiki he ʻelua a keu paha, ua kū ka hopena o glucose i ka pae like ma ka pae.

Hoʻopili pū ʻia ka lāʻau Dapagliflozin e ka diuresis osmotic. Me ka hoʻoponopono o ka lāʻau i wehewehe ʻia, ua loli ʻole ka hopena diuric no 12 mau hebedoma a lilo i 375 ml / lā. Ua ukali ʻia ke kaʻina hana me ka leʻo o ka liʻiliʻi o ka sodium, akā ʻaʻole ia e pili i kēia ʻike i kona ʻike i loko o ke koko.

Lapaʻau lāʻau

  1. Kapehu. Me ka hoʻohana waha, ua maloʻi ʻia ka lāʻau i ka digestive tract a aneane 100%. ʻAʻole pili ke komo i ka meaʻai i ka hopena o ka hoʻopili ʻana. ʻIke ʻia ka kiʻekiʻe o ka hōʻemi ʻana i ka lāʻau ma ke koko ma hope o 2 mau hola i ka wā i hoʻohana ʻia ma ka ʻōpū ʻole. ʻOi aku ka kiʻekiʻe o ka lāʻau o ka lāʻau lapaʻau, ʻoi aku ka kiʻekiʻe o ke kaila o ka plasma i kekahi mau manawa. Ma kahi kanu o 10 mg / lā. ʻo ka bioavailability kūpono piha ma kahi o 78%. I nā poʻe ola olakino ma ka hoʻokolohua, ʻaʻohe ʻai nui i ka ʻai i ka pharmacokinetics o ka lāʻau.
  2. Kahele. Hoʻopaʻa ka lāʻau lapaʻau i nā ʻōnaehana koko ma ka awelika o 91%. Me nā maʻi e koi ʻia, no ka laʻana, ka hemahema o ka renal, e hoʻomau ʻia ana kēia hōʻailona.
  3. Hāpai. ʻO TЅ i ka poʻe olakino he mau hola 12.0 ma hope o hoʻokahi pakahi no kahi papa pāpaona he 10 mg. Hoʻololi ʻia ka Dapagliflozin i loko o ka metabolite inert o dapagliflozin-3-O-glucuronide, ʻaʻohe ona hopena lapaʻau.
  4. ʻAno hānau. Ke puka pū nei ka lāʻau lapaʻau me nā metabolites me ke kōkua o nā keiki i kāna hana kumu. Ma kahi o 75% e hoʻopio ʻia i loko o ka pāʻai, ke koena ma o ka ʻōpū. Ma kahi o 15% o dapagliflozin e puka mai i ka mana kūpono.

Nā hihia kūikawā

ʻO ka nui o ka glucose i hoʻonā ʻia e nā paleha ma nā pilikia o kā lākou hana. Me nā ola olakino, ʻo kēia hōʻailona he 85 g, me kahi ʻano māmā - 52 g, me kahi awelika - 18 g, i nā pilikia koʻikoʻi - 11 g o glucose. Hoʻopili ka mea pale i nā protein i ka hopena like ma ka maʻi maʻi a me ka hui pū. ʻAʻole i aʻo ʻia nā hopena o ka hemodialysis i nā hopena hopena.

I nā hemahema a me ka maʻalahi o ka pīpī pēpē o ka pōpō, hoʻolaʻa ʻia ka pharmacokinetics o Cmax a me AUC ma o 12% a me 36%. ʻAʻole hewa kēlā hewa hewa i kahi mea lapaʻau, no laila, ʻaʻohe mea e pono ai e hōʻemi i ka nui o kēia ʻāpana o ka maʻi maʻi. Ma ke ʻano ikaika, hoʻohālikelike kēia mau kuhikuhi i ka 40% a me 67%.

I ka wā pākeke, ʻaʻole i mālama ʻia ka hoʻololi nui loa i ka hoʻolaha ʻana i ka lāʻau (inā ʻaʻohe kumu ʻē aʻe e hoʻomāinoino ana i ke kiʻi lāʻau lapaʻau). ʻO ka nāwaliwali nā kauā, ʻoi aku ka kiʻekiʻe o ka loaʻa ʻana o dapagliflozin.

I kahi kūlana paʻa, ma nā mea maʻi me ka diabetes type 2, ʻoi aku ka nui o ka Cmax a me AUC ma mua o nā kāne maʻi i ka 22%.

ʻO nā ʻokoʻa i nā hopena i hilinaʻi ʻia no ka lāhui o ʻEulopa, Negroid a i ʻole Mongoloid lāhui i loaʻa.

Me ka nui o ke kaupaona ʻana, ʻoi aku ka liʻiliʻi o nā hōʻailona o ka hopena o ka lāʻau lapaʻau, akā, ʻaʻole i ʻike nui ʻia nā hala, e koi ana i ka hoʻoponopono ʻia.

ʻO wai e pono no ka forsyga

Ke hoʻololi nei i kahi nohona (meaʻaiʻaiʻai haʻahaʻa, lawa ka hoʻoulu ʻana), i mea e hoʻoponopono ai i ka glycemia, hoʻohana ka lāʻau lapaʻau:

  • Me ka monotherapy;
  • Kūlike me ka metformin (inā ʻaʻole lawa ka hopena hypoglycemic);
  • I ka paepae i hoʻonohonoho kū ʻia.

Nā Hoʻohui

  • Hoʻonui kiʻekiʻe i nā mea o nā pulu;
  • ʻAno maʻi type 1;
  • Ketoacidosis;
  • Maʻi nui o ka renal;
  • Ka hoʻomauʻana i ka genetic i ka glucose a me ka lactase;
  • ʻLelo a me ka lactation;
  • ʻO nā keiki a me ʻōpio (ʻaʻohe data hilinaʻi);
  • Ma hope o ka maʻi maʻi, i hele pū ʻia me ke koko;
  • ʻO Senile makahiki (mai 75 mau makahiki) - e like me ka lāʻau mua.

Me nā maʻi genitourinary, pilikia kino, hematocrit kiʻekiʻe, ua kauoha ʻia ka lāʻau lapaʻau me ka mālama.

Nā papahana hana maʻamau

ʻO ke algorithm no ka mālamaʻana o dapagliflozin i ke kauka, akā ke kuhikuhi ʻia nei nā ʻōnaehana maʻamau i nā ʻōlelo kuhikuhi no ka hoʻohana.

  1. Monotherapy. ʻAʻole paʻa ke kaʻaila i ka meaʻai, ʻo ka maʻamau o kēlā me kēia lā he 10 mg i ka manawa.
  2. ʻO ka hoʻolālā holoʻokoʻa. I ka hui me metformin - 10 mg / lā.
  3. ʻO ka papa hana mua. Ma kahi hoʻohālike o Metformin 500 mg / lā. Lawe ka Forsigu i 1 pā. (10g) i kēlā me kēia lā. Inā ʻaʻole i loaʻa ka hopena i makemake ʻia, e hoʻonui i ka hapa o Metformin.
  4. Me nā maʻi hepatic. ʻO ka maʻi maʻi me ka maʻi haʻahaʻa a me ka leʻaleʻa e pono ai i ka hoʻoponopono ʻana i ka wai. Ma ke ʻano ikaika, hoʻomaka lākou me 5 g / lā. Me ke ʻano maʻamau o ke kino, hiki ke hoʻonui ʻia ke ʻano i ka 10 mg / lā.
  5. Me nā mea hoʻohālikelike renal. I ke ʻano paʻakikī a paʻakikī, ʻaʻole i kuhikuhi ʻia ʻo Forsig (i ka wā hana cleince clearance (CC) <60 ml / min.);
  6. Mamua. I ka wā pākeke, ke koho ʻana i kahi regimen lapaʻau, alakaʻi ʻia lākou i ka nui o ke koko a me ke ʻano o nā maʻi.

Nā hopena hopena

ʻO nā haʻawina palekana o ka lāʻau lapaʻau e komo ai i nā mea hana 1,193 i hāʻawi ʻia iā Fortigu ma 10 mg / lā, a me 1393 nā poʻe i lawe i kahi pletebo. ʻO ka pinepine o nā hopena kūpono ʻole like me ka like.

I waena o nā hopena kūlike ʻole e koi ai i ka hoʻokuʻu ʻana o nā ʻoihana, ua ʻike ʻia nā mea penei:

  • Hoʻonui i QC - 0.4%;
  • Nā maʻi e pili ana i ka ʻōnaehana genitourinary - 0.3%;
  • ʻO nā hōʻeha ma ka ʻili - 0.2%;
  • ʻO nā maʻi pāpaʻi;
  • Nā kipi o ka hoʻonohonoho paʻa - 0.2%.

Loaʻa i kekahi mea manawaleʻa ka maʻi hepatitis, akā ua nānā pinepine ʻia ka hypoglycemia, ʻo ka pinepine o kona mau helehelena i hilinaʻi ʻia i ka therapy maʻamau, akā ʻaʻole i ka maʻi o Forsig.

Hōʻike ʻia nā kiko o nā noi ma ka papa ʻaina.

Nā Kūlana loiloi:

  • Pā pinepine pinepine -> 0.1;
  • Iā manawa -> 0,01, <0.1;
  • Ke ʻano -> 0.001, <0.01.

ʻAno o nā ʻōnaehana a me nā ʻāpana

Pinepine pinepine

Pinepine

Ihiau

Nā maʻi a me nā infestations Vulvovaginitis, balanitisWehewehe genital
ʻO ka huʻihuʻi me ka meaʻaiʻaiʻaiHypoglycemia (me ka hoʻohui ʻana o nā hana) Kahuna
Nā maʻi Gastrointestinal  Nā huakaʻi hoʻi
ʻIli kūloko  ʻOhua
ʻŌnaehana musculoskeletal ʻEha i ka pōpilikia 
ʻŌnaehana Genitourinary DysuriaNocturia
ʻIkepili haipule ʻO ka Dyslipidemia, hematocrit kiʻekiʻeʻO ka ulu o QC a me urea i ke koko

Nā Hōʻike Manaʻo Dapagliflozin

Wahi a kahi noiʻi o nā malihini i nā kumuwaiwai papaʻa, ʻo ka hapa nui o nā maʻi maʻi maʻi ʻaʻohe huakaʻi, ua māʻona lākou me nā hopena lapaʻau. Nui ka mea i hoʻopau ʻia e ke kumukūʻai o ka pā, akā ke manaʻo pilikino e pili ana i nā makahiki, nā maʻi concomitant, ka nui o ka lehulehu i hiki ke lilo i alakaʻi no ka hoʻoholo ʻana ma ke koho ʻana iā Forsigi.

Hiki i kahi papa pilikino ke hana aku e ke kauka wale nō, e kāʻili ʻo ia i nā analogues no dapagliflozin (Jardins, Invokuan) inā ʻaʻole i lawa ka paʻakikī.

Ma ke wikiō - nā hiʻohiʻona o Dapagliflozin i kahi ʻano lapaʻau hou.

Pin
Send
Share
Send